我的性奴的肉玩具1一17心奴,天堂a免费视频在线观看,久久久久久欧美精品无码,26uuu国产精品色噜噜

產(chǎn)品資料

HCC1569細(xì)胞

如果您對(duì)該產(chǎn)品感興趣的話,可以
產(chǎn)品名稱: HCC1569細(xì)胞
產(chǎn)品型號(hào): HCC1569
產(chǎn)品展商: HZbscience
產(chǎn)品文檔: 無(wú)相關(guān)文檔

簡(jiǎn)單介紹

HCC1569細(xì)胞應(yīng)如何避免細(xì)胞污染,細(xì)胞污染的種類可分成**、酵母菌、霉菌、病毒和霉?jié){菌。主要的污染原因?yàn)闊o(wú)菌操作技術(shù)不當(dāng)、操作室環(huán)境不佳、污染之血清和污染之細(xì)胞等。嚴(yán)格之無(wú)菌操作技術(shù)、清潔的環(huán)境、與品質(zhì)良好之細(xì)胞來(lái)源和培養(yǎng)基配制是減低污染之*好方法。HCC1569細(xì)胞何時(shí)須更換培養(yǎng)基?視細(xì)胞生長(zhǎng)密度而定,或遵照細(xì)胞株基本數(shù)據(jù)上之更換時(shí)間,按時(shí)更換培養(yǎng)基即可。


HCC1569細(xì)胞  的詳細(xì)介紹

HCC1569細(xì)胞

是否是腫瘤細(xì)胞: 1

物種來(lái)源: 人

生長(zhǎng)狀態(tài): 混合型生長(zhǎng)

器官來(lái)源: **

運(yùn)輸方式: 凍存運(yùn)輸

ATCC Number: CRL-2330?

數(shù)量: 大量

相關(guān)**: 其他**

細(xì)胞形態(tài): 上皮樣

年限: TNM stage IV, grade 3

Designations: HCC1569

Depositors: AF Gazdar, AK Virmani

HCC1569細(xì)胞Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: mixed adherent-suspension

Organism: Homo sapiens

Morphology: epithelial


Source: Organ: mammary gland; breast

Tumor Stage: TNM stage IV, grade 3

Disease: primary metaplastic carcinoma

Cellular Products: Epithelial glycoprotein 2 [EGP2]; cytokeratin 19

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. HCC1569細(xì)胞Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.

Applications: The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR) by immunohistochemistry, but PR expression was detectable at a low level by cytosolic protein assay.

The cells are poorly differentiated.

The cells are positive for expression of Her2-neu and negative for expression of p53.

HCC1569 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.

The cell line is derived from an older patient with a germline mutation in the FHIT gene.

Receptors: estrogen receptor, negative

progesterone receptor, negative

Oncogene: her2/neu +, p53 -

Cytogenetic Analysis: polyploid

Age: 70

Gender: female

Ethnicity: Black

Comments: HCC1569細(xì)胞This cell line was initiated on 3/8/95 and took 19 months to establish.

The patient received prior chemotherapy and had no family history of breast cancer. The tumor was classified as TNM stage IV, grade 3, metaplastic carcinoma with 4 out of 18 lymph node metastasis.

The cells are poorly differentiated.

The cells are positive for expression of Her2-neu and negative for expression of p53.

HCC1569 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.

The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR) by immunohistochemistry, but PR expression was detectable at a low level by cytosolic protein assay.

The cell line is derived from an older patient with a germline mutation in the FHIT gene. The FHIT gene is located at 3p14.2 and the mutation is a transversion at nucleotide 651 (G to T).The patient's daughter carries the same gene mutation.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Temperature: 37.0°C

Atmosphere: air, 95%; carbon dioxide (CO2), 5%

Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended

Protocol:

Remove culture medium to a centrifuge tube.

Briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.

Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually with 5 to 15 minutes).

Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal.

Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.

To remove trypsin-EDTA solution, transfer cell suspension to the centrifuge tube with the medium and cells from step #1 and spin at approximately 125 xg for 5 to 10 minutes.

Discard supernatant and resuspend cells in fresh growth medium. HCC1569細(xì)胞Add appropriate aliquots of cell suspension to new culture vessels.

Place culture vessels in incubators at 37?C.

Preservation: culture medium 95%; DMSO, 5%

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

recommended serum:ATCC 30-2020

References: 32258: Ahmadian M, et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 57: 3664-3668, 1997. PubMed: 9288768

38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771

滬公網(wǎng)安備 31011702004356號(hào)

本溪市| 佳木斯市| 新和县| 安化县| 临桂县| 连平县| 新密市| 嘉义县| 六枝特区| 潮安县| 北川| 宜都市| 乡宁县| 西乌珠穆沁旗| 邛崃市| 房山区| 漳浦县| 柳州市| 彭阳县| 东乌| 东乡| 搜索| 乌兰县| 长阳| 金塔县| 镇坪县| 会同县| 九寨沟县| 佛坪县| 昭平县| 德兴市| 陇西县| 射洪县| 六安市| 藁城市| 蒙阴县| 韩城市| 张家口市| 巨野县| 施秉县| 大姚县|